FAI Advisors, Inc.’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.33M Buy
1,149
+63
+6% +$74.3K 0.52% 40
2026
Q2
$1.3M Buy
1,086
+5
+0.5% +$5.11K 0.51% 39
2026
Q1
$994K Buy
1,081
+3
+0.3% +$3.04K 0.44% 47
2025
Q4
$1.16M Buy
1,078
+12
+1% +$11.5K 0.51% 42
2025
Q3
$813K Buy
1,066
+16
+2% +$11.9K 0.37% 54
2025
Q2
$819K Buy
1,050
+14
+1% +$10.9K 0.4% 50
2025
Q1
$856K Sell
1,036
-4
-0.4% -$3.33K 0.46% 47
2024
Q4
$803K Buy
+1,040
New +$861K 0.36% 59

Other funds holding LLY

FAI Advisors, Inc.'s LLY Position: Q3 2026 in Review

FAI Advisors, Inc. increased its Eli Lilly (LLY) stake by 5.8% in Q3 2026, buying an estimated $74.3K and bringing the position to 1,149 shares worth $1.33M. The position accounts for 0.52% of the portfolio, ranked #40.

FAI Advisors, Inc. first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 1,741 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • FAI Advisors, Inc. held 1,149 shares of Eli Lilly worth $1.33M as of Q3 2026.
  • FAI Advisors, Inc. bought 63 Eli Lilly shares in Q3 2026, an estimated $74.3K.
  • Eli Lilly made up 0.52% of FAI Advisors, Inc.'s portfolio in Q3 2026, its #40 holding.
  • FAI Advisors, Inc. first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 1,741 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on FAI Advisors, Inc.'s 13F filing for Q3 2026, filed 27 Oct 2026.